WuXi Biologics (Cayman) Inc

WuXi Biologics maintains a conservative capital structure characterized by low leverage and strong liquidity. The debt-to-equity ratio stands at 0.07, indicating minimal reliance on debt financing relative to shareholder equity. The current ratio of 3.39 suggests ample short-term assets to cover liabilities, supporting a medium liquidity risk assessment. Despite the strong current ratio, the risk assessment flags that net cash is negative after subtracting total debt, implying that cash and equivalents are lower than total liabilities including long-term debt of 3.1 billion CNY. The company generates substantial operating cash flow of 6.34 billion CNY, which exceeds its capital expenditure of 3.69 billion CNY, resulting in positive free cash flow of 3.79 billion CNY.

Profitability metrics demonstrate efficient operations, with a net income of 4.91 billion CNY on revenue of 21.79 billion CNY. The return on equity (ROE) is 10.39%, and return on assets (ROA) is 7.71%. The gross profit of 10.02 billion CNY indicates a gross margin of approximately 46%, while operating income of 7.40 billion CNY reflects strong operational leverage. The valuation multiples reflect a premium positioning, with a price-to-earnings (P/E) ratio of 32.05 and an EV/EBITDA of 21.67. The price-to-book ratio is 3.33, aligning with the tangible book value multiple.